Last reviewed · How we verify
Merck & Co. — Portfolio Competitive Intelligence Brief
MRK (NYSE)
75 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Winrevair | SOTATERCEPT | marketed | Cardiovascular | 2025-01-01 | ||
| Welireg | BELZUTIFAN | marketed | Hypoxia-inducible Factor Inhibitor [EPC] | HIF-2α | Oncology | 2021-01-01 |
| Verquvo | VERICIGUAT | marketed | Soluble Guanylate Cyclase Stimulator [EPC] | Guanylate cyclase soluble subunit beta-1 | Cardiovascular | 2021-01-01 |
| Recarbrio | RELEBACTAM | marketed | Renal Dehydropeptidase Inhibitor [EPC] | Infectious Disease | 2019-01-01 | |
| Pifeltro | DORAVIRINE | marketed | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | Immunology | 2018-01-01 | |
| Bavencio | avelumab | marketed | Programmed Death Ligand-1 Blocker [EPC] | Programmed cell death 1 ligand 1 | Oncology | 2017-01-01 |
| Steglatro | ERTUGLIFLOZIN | marketed | Low affinity sodium-glucose cotransporter | Metabolic | 2017-01-01 | |
| Prevymis | LETERMOVIR | marketed | Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] | Infectious Disease | 2017-01-01 | |
| Zepatier | ELBASVIR | marketed | Hepatitis C Virus NS5A Inhibitor [EPC] | Oncology | 2016-01-01 | |
| Zinplava | BEZLOTOXUMAB | marketed | Infectious Disease | 2016-01-01 | ||
| Keytruda | pembrolizumab | marketed | Monoclonal antibody; PD-1 inhibitor | PD-1 receptor | Oncology | 2014-01-01 |
| Victrelis | BOCEPREVIR | marketed | Hepatitis C Virus NS3/4A Protease Inhibitor | Chymase | Infectious Disease | 2011-01-01 |
Therapeutic area mix
- Other · 13
- Oncology · 12
- Immunology · 11
- Cardiovascular · 11
- Infectious Disease · 10
- Metabolic · 10
- Neuroscience · 4
- Bone · 3
- Hematology · 2
- Urology · 1
Recent regulatory actions (last 90 days)
- — Stromectol · FDA · approved · US
- — WINREVAIR · FDA · approved · US
- — Winrevair · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Proventil · 7500444*PED · US
- — Proventil · 7396341 · US
- — Elocon · 7544192 · Method of Use · US
- — Proventil · 9027967 · US
- — Zocor · 10300041 · Formulation · US
- — Ortho-Novum 10/11-21 · 7838042 · US
- — Elocon · 8025635 · Formulation · US
- — Proventil · 7837235 · US
- — Proventil · 8651103 · US
- — Zosyn · 7129232 · US
- — Ortho-Novum 10/11-21 · 9050348 · US
- — Ortho-Novum 10/11-21 · 8747888 · US
- — Ortho-Novum 10/11-21 · 8246978 · US
- — Proventil · 8132712 · US
- — Ortho-Novum 10/11-21 · 7855190 · US
- — Ortho-Novum 10/11-21 · 7704984 · US
- — Ortho-Novum 10/11-21 · 8415332 · US
- — Zepatier · 7973040 · US
- — Zepatier · 7973040 · US
- — Primaxin · 8487093 · US
- — Primaxin · 8487093 · US
- — Recarbrio · 8487093 · US
- — Ortho-Novum 10/11-21 · 8617597 · US
- — Dexamethasone Sodium Phosphate · 8563027 · Method of Use · US
- — Decadron-La · 8563027 · Method of Use · US
- — Zocor · 9597289 · Formulation · US
- — Dexamethasone Sodium Phosphate · 8409606 · Formulation · US
- — Decadron-La · 8409606 · Formulation · US
- — Proventil · 9415009 · US
- — Ortho-Novum 10/11-21 · 11617751 · US
Competitive overlap (companies sharing drug classes)
- · 18 shared drug classes
- Pfizer · 8 shared drug classes
- AbbVie · 5 shared drug classes
- Bristol-Myers Squibb · 5 shared drug classes
- Novartis · 3 shared drug classes
- GlaxoSmithKline · 3 shared drug classes
- Boehringer Ingelheim · 3 shared drug classes
- Bayer · 3 shared drug classes
Subscribe to ongoing alerts
Every new pipeline event for Merck & Co.:
- Merck & Co. pipeline updates — RSS
- Merck & Co. pipeline updates — Atom
- Merck & Co. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Merck & Co. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/merck. Accessed 2026-05-13.